Clopidogrel and Response Variability Investigation Study 2
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the role of the genetic variant 2C19*2 on the pharmacodynamic response as
assessed by optical aggregometry and on the pharmacokinetic response as assessed by measuring
active metabolites following an oral administration of a loading dose of 300/900mg of
clopidogrel in patients with established coronary artery disease.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France